| News & Announcements | Coverage Expansion of Respiratory Syncytial Virus Vaccine (Abrysvo) for Commercial Members (Retroactively Effective October 22, 2024) | | | | | | 12/23/2024 | | | |
| Notifications | Tofersen (Qalsody®) | 08.02.06b | 12/2/2024 9:00 AM | 1/1/2025 | | | 12/2/2024 | Coverage and/or Reimbursement Position | | |
| Notifications | Medical Nutrition Therapy (MNT)/Nutrition Counseling | 10.00.04 | 12/2/2024 2:00 PM | 1/1/2025 | | | 12/2/2024 | This is a New Policy. | | |
| Notifications | Drugs, Biologics, or Gene Therapies with an Accelerated Approval | 08.02.35 | 12/2/2024 2:00 PM | 1/1/2025 | | | 12/2/2024 | This is a New Policy. | | |
| Notifications | Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer Disease | 08.01.93e | 12/2/2024 3:00 PM | 1/1/2025 | | | 12/2/2024 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Notifications | Exon Skipping Drugs for Duchenne Muscular Dystrophy (DMD) (Eteplirsen (Exondys 51), Golodirsen (Vyondys 53), Viltolarsen (Viltepso)), Casimersen (Amondys 45) | 08.01.34d | 12/2/2024 3:00 PM | 1/1/2025 | | | 12/2/2024 | Coverage and/or Reimbursement Position;Medical Necessity Criteria | | |
| Notifications | eviCore Lab Management (AmeriHealth) | 06.02.52ai | 12/2/2024 5:00 PM | 1/1/2025 | | | 12/2/2024 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Notifications | Total Parenteral Nutrition (TPN) / Intradialytic Parenteral Nutrition (IDPN) / Intraperitoneal Parenteral Nutrition (IPN) | 08.00.17k | 12/3/2024 9:00 AM | 1/1/2025 | | | 12/3/2024 | Medical Necessity Criteria | | |
| Notifications | Casgevy™ (exagamglogene autotemcel) | 08.02.14 | 12/3/2024 11:00 AM | 1/1/2025 | | | 12/3/2024 | This is a New Policy. | | |
| Notifications | Lovotibeglogene autotemcel (Lyfgenia®) | 08.02.15 | 12/3/2024 11:00 AM | 1/1/2025 | | | 12/3/2024 | This is a New Policy. | | |
| Notifications | Fetal Surgery | 11.00.03m | 12/3/2024 3:00 PM | 1/1/2025 | | | 12/3/2024 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Notifications | Delandistrogene moxeparvovec (delandistrogene moxeparvovec-rokl; Elevidys®) | 08.02.13a | 12/3/2024 5:00 PM | 1/1/2025 | | | 12/3/2024 | General Description, Guidelines, or Informational Update | | |
| Notifications | Treatment of Varicose Veins of the Lower Extremities and Perforator Vein Incompetence | 11.02.01t | 12/13/2024 11:00 AM | 1/13/2025 | | | 12/13/2024 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Notifications | Modifier 50: Bilateral Procedure | 03.00.05z | 12/13/2024 2:00 PM | 1/13/2025 | | | 12/13/2024 | Medical Coding | | |
| Notifications | Modifier 62: Two Surgeons | 00.10.11ab | 12/13/2024 2:00 PM | 1/13/2025 | | | 12/13/2024 | Medical Coding | | |
| Notifications | Direct Endoscopic Necrosectomy (DEN) for the Treatment of Pancreatic Necrosis | 11.03.16 | 12/17/2024 12:00 PM | 1/20/2025 | | | 12/17/2024 | This is a New Policy. | | |
| Notifications | Epidural, Paravertebral Facet, and Sacroiliac Joint Injections for Spinal Pain Management (Amerihealth Administrators) | 11.15.23l | 12/17/2024 12:00 PM | 3/17/2025 | | | 12/17/2024 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Notifications | Apheresis Therapy | 06.03.04o | 12/17/2024 1:00 PM | 3/17/2025 | | | 12/17/2024 | Medical Necessity Criteria | | |
| Notifications | Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer | 06.02.53 | 12/23/2024 10:00 AM | 1/27/2025 | | | 12/23/2024 | This is a New Policy. | | |
| New Policies | Atidarsagene autotemcel (Lenmeldy) | 08.02.24 | | 12/23/2024 | | | 12/23/2024 | This is a New Policy. | | |
| New Policies | Crovalimab-akkz (Piasky) | 08.02.31 | | 1/1/2025 | | | 12/30/2024 | This is a New Policy. | | |
| New Policies | Casgevy™ (exagamglogene autotemcel) | 08.02.14 | 12/3/2024 11:00 AM | 1/1/2025 | | | 12/30/2024 | This is a New Policy. | | |
| New Policies | Lovotibeglogene autotemcel (Lyfgenia®) | 08.02.15 | 12/3/2024 11:00 AM | 1/1/2025 | | | 12/30/2024 | This is a New Policy. | | |
| New Policies | Fidanacogene elaparvovec-dzkt (Beqvez™) | 08.02.25 | | 12/30/2024 | | | 12/30/2024 | This is a New Policy. | | |
| Updated Policies | Gender-Affirming Interventions | 11.09.02p | | 11/27/2024 | | | 12/2/2024 | General Description, Guidelines, or Informational Update | | 12/2/2024 |
| Updated Policies | Denervation of the Spinal Nerves for Chronic Pain (Amerihealth Administrators) | 11.15.09r | | 12/2/2024 | | | 12/2/2024 | Coverage and/or Reimbursement Position;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Cerliponase alfa (Brineura®) | 08.01.39d | | 12/2/2024 | | | 12/2/2024 | Medical Necessity Criteria | | |
| Updated Policies | Therapeutic Transcranial Magnetic Stimulation (TMS) | 07.03.22f | 11/1/2024 1:00 PM | 12/2/2024 | | | 12/2/2024 | Medical Necessity Criteria | | |
| Updated Policies | Gender-Affirming Interventions | 11.09.02p | | 11/27/2024 | | | 12/2/2024 | General Description, Guidelines, or Informational Update | | |
| Updated Policies | Lumasiran (Oxlumo®) | 08.01.74a | | 12/2/2024 | | | 12/2/2024 | Medical Necessity Criteria | | |
| Updated Policies | PPO Network Rules for Provision of Specialty Services for Durable Medical Equipment and Laboratory, Radiology, and Physical Medicine and Rehabilitative Services | 00.01.25bq | | 12/16/2024 | | | 12/16/2024 | Coverage and/or Reimbursement Position | | |
| Updated Policies | New Jersey Health Maintenance Organization (HMO) and Health Maintenance Organization Point-of-Service (HMO-POS) Radiology Network Rules and Limited Circumstances | 00.01.55y | | 12/16/2024 | | | 12/16/2024 | Coverage and/or Reimbursement Position | | |
| Updated Policies | Radiation Therapy Services (AmeriHealth Administrators) | 09.00.56s | | 10/1/2024 | | | 12/16/2024 | Medical Necessity Criteria | | |
| Updated Policies | Reconstructive Breast Surgery and Post-Mastectomy Prostheses | 11.08.15ab | | 10/21/2024 | | | 12/16/2024 | Medical Necessity Criteria | | |
| Updated Policies | Reimbursement for Radiopharmaceutical Agents for Professional Providers | 09.00.32ag | | 12/16/2024 | | | 12/16/2024 | Coverage and/or Reimbursement Position | | |
| Updated Policies | Prescription Lenses and Visual Devices | 07.13.13g | | 12/30/2024 | | | 12/30/2024 | Coverage and/or Reimbursement Position | | |
| Updated Policies | Intravenous Infliximab and Related Biosimilars | 08.00.34u | | 1/1/2025 | | | 12/30/2024 | Medical Necessity Criteria | | |
| Updated Policies | Canakinumab (Ilaris®) | 08.01.51c | | 1/6/2025 | | | 12/30/2024 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Self-Administered Drugs and Biologics | 08.00.78at | | 1/1/2025 | | | 12/30/2024 | Coverage and/or Reimbursement Position;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Coagulation Factors | 08.00.92ah | | 1/6/2025 | | | 12/30/2024 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Avelumab (Bavencio®) | 08.01.64d | | 1/6/2025 | | | 12/30/2024 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Bevacizumab (Avastin®) and Related Biosimilars For Oncologic Use | 08.00.66w | | 1/1/2025 | | | 12/30/2024 | Medical Necessity Criteria | | |
| Updated Policies | Multiple Surgery Payment Reduction | 11.00.10y | | 12/30/2024 | | | 12/30/2024 | Medical Coding;General Description, Guidelines, or Informational Update | | |
| Updated Policies | Leuprolide Acetate (Camcevi™, Eligard®, Fensolvi®, Lupron Depot®) | 08.01.33j | | 1/6/2025 | | | 12/30/2024 | Medical Necessity Criteria | | |
| Updated Policies | Ipilimumab (Yervoy®) | 08.01.01n | | 1/6/2025 | | | 12/30/2024 | Medical Necessity Criteria | | |
| Updated Policies | Delandistrogene moxeparvovec (delandistrogene moxeparvovec-rokl; Elevidys®) | 08.02.13a | 12/3/2024 5:00 PM | 1/1/2025 | | | 12/31/2024 | General Description, Guidelines, or Informational Update | | |
| Reissue Policies | Neuropsychological Testing for Neurologically Based Conditions | 07.03.08o | | 10/1/2023 | 10/16/2024 | | 12/4/2024 | | | |
| Coding Update | Hair Transplants and Cranial Prostheses (Wigs) | 11.08.01h | | 10/1/2024 | 10/1/2024 | | 12/2/2024 | | 12/2/2024 | |
| Coding Update | Home Prothrombin Time Monitoring | 05.00.26l | | 10/1/2024 | 10/1/2024 | | 12/2/2024 | | 12/2/2024 | |
| Coding Update | Hematopoietic Stem Cell Transplantation (Bone Marrow Transplant) | 11.07.01z | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Radiation Therapy Services | 09.00.56t | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) | 07.13.06o | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Wound Care: Skin Substitutes for the Treatment of Burns and Chronic, Non-Healing Wounds | 11.08.20an | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Coverage of Anticancer Prescription Oral and Injectable Drugs and Biologics and Supportive Agents | 08.01.08s | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Maintenance Treatment of Opioid or Alcohol Use Disorder | 08.01.37e | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension) | 08.00.90s | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Catheter Ablation of Cardiac Arrhythmias | 11.02.06r | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Insulin Pumps and Long-Term Interstitial Continuous Glucose Monitoring Systems | 05.00.79k | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Magnetic Resonance Imaging (MRI)-Guided Focused Ultrasound Ablation | 11.06.06h | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Musculoskeletal Services (AmeriHealth) | 00.01.66o | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Routine/Non-routine Vaccines | 08.01.04af | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Telemedicine Services | 00.10.41n | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Telemedicine and Telehealth Services for AmeriHealth New Jersey Members | 00.10.42g | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Fertility Preservation (AmeriHealth New Jersey) | 07.10.08e | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Chimeric Antigen Receptor (CAR) Therapy | 08.01.43o | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Trastuzumab (Herceptin®) and Related Biosimilars, Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta) | 08.00.33s | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris®) for intravenous administration | 08.00.84k | | 1/1/2025 | | | 12/31/2024 | | | |
| Coding Update | Bariatric Surgery | 11.03.02u | | 10/1/2024 | | | 12/31/2024 | | | |
| Archived Policies | Treatment of Twin-Twin Transfusion Syndrome (TTTS) | 11.00.14g | 11/29/2024 1:00 PM | 1/2/2025 | | | 12/2/2024 | | | |